Skip to NavigationSkip to content

FDA approves first extended depth of focus lenses for people with cataracts

Published on 18/07/16 at 10:34am

Abbott has announced that the Tecnis Symfony Intraocular Lenses for the treatment of cataracts has been approved by the US Food and Drug Administration.

The lens becomes the first intraocular lens that provides cataract patients with an extended depth-of-focus, which helps improve their sharpness of vision at near, intermediate and far distances.

Almost four million cataract surgeries are performed in the US each year and, by the age of 80, more than half of all Americans either have a cataract or have had cataract surgery.

In clinical studies, it has been shown that the Symfony lens provided seamless day-to-night vision and demonstrated a low incidence of halo and glare.

Eric D. Donnenfeld, a New York-based ophthalmic consultant, says: “Many of my patients live very active lifestyles and want to see clearly at all distances, and without glasses if possible. With the Symfony lens, I can give patients the freedom to enjoy the activities that matter to them, while wearing glasses less.”

Thomas Frinzi, senior vice president of Abbott’s vision business, adds: “This is an important addition to our portfolio of lenses, as we expect many patients to choose a Symfony lens over a standard monofocal lens, given its benefits. We are happy that we can offer more people around the world this new category of lenses.”

Sean Murray

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches